SAB Biotherapeutics (NASDAQ:SABS) Announces Earnings Results, Beats Expectations By $0.38 EPS

SAB Biotherapeutics (NASDAQ:SABS) posted its earnings results on Friday. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.38, Zacks reports.

SAB Biotherapeutics Stock Performance

NASDAQ SABS opened at $3.24 on Friday. The stock has a 50-day simple moving average of $2.59 and a two-hundred day simple moving average of $2.23. The firm has a market capitalization of $33.73 million, a P/E ratio of -1.05 and a beta of 0.60. SAB Biotherapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $6.60. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.87 and a current ratio of 0.87.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Leerink Partners assumed coverage on SAB Biotherapeutics in a research report on Wednesday, September 17th. They set an “outperform” rating and a $7.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of SAB Biotherapeutics in a research note on Tuesday. Chardan Capital reaffirmed a “buy” rating and issued a $12.00 price objective on shares of SAB Biotherapeutics in a research report on Friday, September 19th. HC Wainwright decreased their price objective on shares of SAB Biotherapeutics from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Tuesday, July 22nd. Finally, Wall Street Zen raised shares of SAB Biotherapeutics to a “sell” rating in a research report on Saturday, September 20th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, SAB Biotherapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $9.33.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of SABS. Virtu Financial LLC acquired a new stake in SAB Biotherapeutics in the third quarter valued at approximately $40,000. ADAR1 Capital Management LLC purchased a new stake in shares of SAB Biotherapeutics during the third quarter worth about $30,000. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of SAB Biotherapeutics during the third quarter worth about $32,000. 7.82% of the stock is owned by institutional investors and hedge funds.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.